QTTB

Q32 Bio is a clinical-stage biotechnology company developing therapies targeting the complement pathway for immune-mediated diseases. The company focuses on conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Q32 Bio uses a precision approach to modulate specific complement components, aiming for targeted efficacy with reduced side effects compared to broader immunosuppression.